3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
44
Lymphoma, Mantle-Cell
22
Lymphoma, Non-Hodgkin
15
Lymphoma, Large B-Cell, Diffuse
13
Lymphoma, Follicular
10
Waldenstrom Macroglobulinemia
9
Lymphoma
9
Lymphoma, B-Cell, Marginal Zone
7
Leukemia
7
Recurrence
6
Neoplasms
6
Lymphoma, B-Cell
5
Leukemia, B-Cell
5
Bronchiolitis Obliterans Syndrome
5
Multiple Myeloma
3
Leukemia, Lymphoid
3
Hematologic Diseases
3
Graft vs Host Disease
3
Burkitt Lymphoma
3
Melanoma
2
Leukemia, Prolymphocytic
2
Leukemia, Hairy Cell
2
Hematologic Neoplasms
2
Glioblastoma
2
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Central Nervous System Lymphoma (PCNSL)
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neurologic Manifestations
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
ibrutinib
×
1 year
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled